Teleflex (TFX) News
NYSE: TFXHealth CareMedical/Dental InstrumentsUSD
125.12+0.93 (+0.75%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
TFX news summary
We found 7 recent headlines mentioning Teleflex (TFX): 0 in the past week and 4 in the past 30 days, most often from Nasdaq. For price context, TFX is up 0.75% at $125.12. The most recent story, "Boston Scientific's MedSurg Diversification Bolsters Growth Prospects", was published by Nasdaq on Sep 30, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Teleflex headlines
- Boston Scientific's MedSurg Diversification Bolsters Growth ProspectsBSX's MedSurg segment supports growth, with Endoscopy and Neuromodulation gains offsetting Urology challenges and portfolio gaps.NasdaqBSX, MDT, TFX
- Illumina Stock Surges 94.9% YTD: What's Behind the Rally?ILMN's 94.9% YTD rally reflects strong sequencing growth, clinical adoption and a raised 2026 outlook despite China headwinds.NasdaqILMN, TFX, GMED, VCYT
- Should You Continue to Hold IDXX Stock in Your Portfolio?IDEXX's CAG growth, expanding software adoption and global gains face headwinds from FX and weaker U.S. vet visits.NasdaqIDXX, TFX, GMED, VCYT
- IDEXX Stock Gains Following the Acquisition of CoVetIDXX shares rise 0.6% after the company acquires CoVet, expanding its AI-native software capabilities to improve veterinary workflows, diagnostics and practice performance.NasdaqIDXX, TFX, GMED, VCYT
- Can Teleflex's OEM Sale and Higher EPS Outlook Reshape 2026 Returns?TFX's $1.5B OEM sale cuts leverage and lifts 2026 EPS guidance, but weaker growth and margin pressure keep the outlook measured.NasdaqTFX, BSX, BDX
- Is it a Prudent Move to Retain IDEXX Stock in Your Portfolio Now?IDXX's CAG diagnostics and cloud software growth support recurring revenues, while FX exposure and distributor inventory swings remain key risks.NasdaqIDXX, TFX, GMED, VCYT
- Should You Hold Edwards Lifesciences Stock in Your Portfolio?EW's TAVR and TMTT growth support its outlook, but currency pressure and intense competition remain key risks.NasdaqEW, TFX, GMED, VCYT